By Dave Sebastian 



  Ideaya Biosciences Inc. and Pfizer Inc. are extending their clinical-trial collaboration and supply agreement for a combination therapy of patients with solid tumors, with certain mutations, including metastatic uveal melanoma, skin melanoma, lung cancer and colorectal cancer, Ideaya said. 


  The move involves an Ideaya-sponsored clinical combination study of IDE196, a protein kinase C inhibitor, and crizotinib, a cMET inhibitor to which Pfizer has exclusive rights, Ideaya said Thursday. The solid tumors being evaluated are those with GNAQ or GNA11 mutations. 


  Ideaya said it would sponsor the study, while Pfizer will provide the crizotinib drug supply. 


  "Through our translational research we have identified cMET expression as a potential biomarker, and we are excited to explore this rational combination between IDE196 and crizotinib clinically," said Mark Lackner, Ideaya's head of biology and translational sciences. 


  Ideaya said it is targeting its first patient for the crizotinib clinical trial combination in late 2020 to early 2021. It said it is also evaluating IDE196 as a monotherapy in additional tumor types, including skin melanoma. 


  Write to Dave Sebastian at dave.sebastian@wsj.com